spacer
home > ebr > summer 2003 > the biotech juggling act
PUBLICATIONS
European Biopharmaceutical Review

The Biotech Juggling Act

The completed sequencing of the human genome was a tremendous achievement but only 30 months later, the long-term knock on to the drug discovery industry is becoming apparent. The prediction is that by 2005 about half of all new products will come out of biotech; presumably this is why there are over 4,000 biotech-focused companies (approximately 10 per cent of which are public) out there.

Throughout these organisations computer-based research studies are increasing, and notably they are developing independently of the laboratory. Well-integrated information systems (IS) may one day develop into the primary R&D environment, with analytical laboratories reduced to a secondary role of investigative analysis and manufacturing. Consequently, I find myself wondering: how long before computer-based research overhauls traditional biological research and development?

Before I cause too much anxiety in the wet laboratory-based scientific community, let me elucidate what I mean by computer-based research. My view is that it includes, but is not restricted to, what many of you may already be thinking, namely the growing field of bioinformatics.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Geoff Parker, Commercial Director at Scimcon

Geoff Parker is Commercial Director at scientific information management consultancy Scimcon, where he is responsible for global sales and customer support. Geoff has a particular focus on data management strategy consultancy and enjoys a hands-on role advising clients on their information system requirements and system selection.

Before joining Scimcon in June 2000, Geoff spent two years with laboratory information system provider Thermo LabSystems. Prior to working in the lab information systems field, Geoff had a background in chemistry, working as a Technical Chemist, after which he spent five years working for a major technology supplier.

spacer
Geoff Parker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Annual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.20 per share

Duesseldorf, June 24, 2020—Payment of a dividend of EUR 1.20 per share was approved at the virtual Annual General Meeting of Gerresheimer AG.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement